A practical reference on GW501516: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-19. Anything still debated is marked as such rather than presented as settled.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Hydrolysis of peptides of at least six residues, with bulky hydrophobic residues in the P1' position. Shows a preference for hydrophobic doublets such as -Phe-Phe- and -Phe-Leu- in somatostatin-(1-14)-peptide and dynorphin A-(1-6)-peptide, respectively This endopeptidase in the skin of the amphibian, Xenopus laevis.
On 26 February, after setting 737 of Kuwait's oil wells on fire, Iraqi troops began retreating. A long convoy of retreating Iraqi troops formed along the main Iraq–Kuwait highway. This convoy was bombed so extensively by coalition air forces that it came to be known as the Highway of Death. Thousands of Iraqi troops were killed. American, British, and French forces continued to pursue retreating Iraqi forces over the border and back into Iraq, eventually moving to within 240 km (150 mi) of Baghdad, before withdrawing back to Iraq's border with Kuwait and Saudi Arabia.
==== Delirium ==== A systematic review, published in 2014, concluded "ramelteon was found to be beneficial in preventing delirium in medically ill individuals when compared to placebo." A 2022 systematic review and meta-analysis found that the combination of ramelteon and the orexin receptor antagonist suvorexant may reduce the incidence of delirium in adults hospitalized patients whereas suvorexant alone was ineffective.
Schabowski gave a confusing answer that asserted it was necessary because West Germany had exhausted its capacity to accept fleeing East Germans, then remembered the note he had been given and added that a new regulation had been drafted to allow permanent emigration at any border crossing. This caused a stir in the room; amid several questions at once, Schabowski expressed surprise that the reporters had not yet seen this regulation, and started reading from the note. After this, a reporter, either Ehrman or Bild-Zeitung reporter Peter Brinkmann, both of whom were sitting in the front row at the press conference, asked when the regulations would take effect. After a few seconds' hesitation, Schabowski replied, "As far as I know, it takes effect immediately, without delay" (German: Das tritt nach meiner Kenntnis ... ist das sofort ... unverzüglich). This was an apparent assumption based on the note's opening paragraph; as Beil attempted to interject that it was up to the Council of Ministers to decide when it took effect, Schabowski proceeded to read this clause, which stated it was in effect until a law on the matter was passed by the Volkskammer. Crucially, a journalist then asked if the regulation also applied to the crossings to West Berlin. Schabowski shrugged and read item 3 of the note, which confirmed that it did. After this exchange, Daniel Johnson of The Daily Telegraph asked what this law meant for the Berlin Wall. Schabowski sat frozen before giving a rambling statement about the Wall being tied to the larger disarmament question.
=== Influences === β-TG levels may increase with age. It is elevated in diabetes mellitus. β-TG levels have been found to be increased by treatment with the synthetic estrogen ethinylestradiol, though were not significantly increased by the natural estrogen estradiol valerate. Levels of β-TG have also been found to be increased or unchanged during normal pregnancy.
Sources: en.wikipedia.org
John J. Abel Award Julius Axelrod Award Pharmacia-ASPET Award in Experimental Therapeutics Robert R. Ruffolo Career Achievement Award Travel Award for Pharmacology Educators Bernard B. Brodie Award in Drug Metabolism P.B. Dews Lifetime Achievement Award for Research in Behavioral Pharmacology Drug Metabolism Early Career Achievement Award Goodman and Gilman Award in Receptor Pharmacology Benedict R. Lucchesi Distinguished Lectureship in Cardiac Pharmacology Torald Sollmann Award in Pharmacology Paul M. Vanhoutte Distinguished Lectureship in Cardiovascular Pharmacology Travel awards to participate in its meetings are also given to students and postdocs. Chemotherapy Clinical pharmacology Drug metabolism Neuropharmacology Pharmacology Toxicology Official website Molecular Interventions magazine
== Zirconium-88 == 88Zr is a radioisotope of zirconium with a half-life of 83.4 days. In January 2019, this isotope was discovered to have a thermal neutron capture cross section of approximately 861,000 barns; this is several orders of magnitude greater than predicted, and greater than that of any other nuclide except xenon-135.
On 26 September, Trump rejected Iran's seven-day ceasefire proposal and expressed doubt that Tehran would eventually comply with his administration's nuclear demands. In a phone interview the following day, Trump said that he still expected more talks with Iran to resume during the week. Trump claimed that Iran "wanted to make a deal," but they "overplayed their hand" by offering conditions that the US "would have maybe agreed to a year ago." By late September 2026, crude oil and petroleum flows through the Strait of Hormuz had recovered to 77% to 80% of pre-war levels, totaling an estimated 13.19 million barrels per day. A US Navy campaign that used armed convoy escorts and unmonitored "dark transits" was responsible for the stabilization of shipping traffic. Iran's own oil and petrochemical exports were severely limited at the same time due to the combined effects of an active US naval blockade and a broad secondary sanctions campaign known as Operation Economic Outcast. This economic contraction drove the Iranian rial to a historic low of 2.5 million rials per U.S. dollar, significantly eroding Iran's primary geopolitical leverage against Washington. Despite the decline in its conventional enforcement capabilities, the IRGC maintained asymmetric tactics, ensuring maritime insurance premiums remained highly elevated. As worries about Iranian retaliation grew, the US military sent two more Patriot missile batteries to Saudi Arabia and Qatar in September 2026 to safeguard vital energy infrastructure.
In July 2023, the paper announced it will reduce its print schedule to three days a week: Tuesday, Thursday and Saturday. Also, the newspaper will transition from carrier to postal delivery. In September 2024, Napa Valley Publishing, which publishes the paper, was sold by Lee Enterprises to Hoffmann Media Group.
==== Divestiture of oil and gas interests ==== In 1993, Grace Drilling was sold to Nabors Loffland Drilling Company, a Nabors Industries subsidiary, for approximately $32 million, and Grace Petroleum Corporation was sold to an undisclosed buyer for $125 million, with its East Texas oilfields being sold to Samson Investment Company for $38 million. Grace agreed at that time to sell the following companies:
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.